Canada: 2010 Ontario Drug System Reforms

Last Updated: April 20 2010
Most Read Contributor in Canada, November 2017

Article by Jeffrey S. Graham , Bonnie Freedman and Stephen Andrews

The Government of Ontario has released its proposals for changes to the drug system in Ontario, following a public consultation process that began in June 2009. In its budget bill tabled in the Provincial Legislature on March 25, 2010, the Government announced plans to delete the professional allowance exemption from the definition of the term "rebate" in the Ontario Drug Benefit Act (ODBA) and the Drug Interchangeability and Dispensing Fee Act (DIDFA).

More recently, on April 8, 2010, the Government of Ontario released for public comment, changes to regulations made pursuant to the ODBA and DIDFA. Together, the proposed legislative and regulatory changes represent very significant reforms of the rules regarding the sale of drugs in Ontario. Set out below, is a summary of the key elements of the proposed changes and some of the implications for key stakeholders.


The Government notes that the most recent reforms of the drug system, implemented in 2006, have resulted in savings of $1 billion, but that the rules defining the circumstances in which manufacturers can pay professional allowances (PAs) to pharmacies and operators of pharmacies have not worked well.

PAs have traditionally been paid by manufacturers of interchangeable generic drugs to pharmacies. In Ontario, in distinction to physicians, pharmacists do not receive fees for many of their core professional activities so that the prohibition on rebates, that was introduced with the 2006 drug system reform, gave rise to discussion of the appropriate funding model for pharmacy services. The Government defines the method of calculating and reporting PAs, which has involved distinguishing whether a PA has been paid in connection with the sale of drugs to individuals on a Government-sponsored drug plan or otherwise. The Government reimburses a portion of the cost of drugs listed on the Government's formulary (Formulary). In the past, the Formulary price (ODB price) has not necessarily been the price for non-ODB sales.


Limits on Generic Drug Prices

Based on the current version of the proposed regulations, which are to come into effect on May 15, 2010, generally, the maximum ODB price for generic drugs is reduced from 50% to 25% of the brand name product price. For sales in the private market (non-ODB sales covered by private insurance or the consumer), effective May 15, 2010, the maximum price for generic drugs will generally be the higher of 50% of the brand price (as of the date the product was first proposed for interchangeability) or the ODB price. The 50% drops to 35% effective April 1, 2011. Effective April 1, 2012, a manufacturer must not sell a generic drug at more than the ODB price, whether the product is dispensed in the public (ODB) or the private market.

Limits on PAs

Based on the current proposed regulations, effective May 15, 2010, PAs for non-ODB sales will be capped at 50% of the total dollar amount of interchangeable products sold in the private market (calculated as the number of units multiplied by the ODB price). The cap on PAs on non-ODB sales will be reduced to a maximum of 35% on April 1, 2011. On April 1, 2012, PAs on non-ODB sales will be capped at 25%. Effective May 15, 2010, PAs on ODB sales will be capped at 5%.

The definition of rebate (which will remain a prohibited payment), is being revised to exclude ordinary commercial terms from what is prohibited. Ordinary commercial terms is proposed to be defined generally as a benefit provided in the ordinary course of business on the sale of interchangeable products, the value of which is set out in a written agreement, and must relate to an ordinary commercial relationship that is (i) a prompt payment discount, (ii) a volume discount, or (iii) a distribution fee. (For listed drug products that are not interchangeable, the permitted benefit is limited to a prompt payment discount.)

Effective May 15, 2010, pharmacists will no longer be required to report PAs (manufacturers will continue to be required to report, notwithstanding the recent difficulties they have faced in calculating the proper amounts to report).

The Executive Officer (EO) is to have new powers to require a manufacturer to inform the EO of the price the manufacturer receives for a drug product listed on the Government formulary or an interchangeable drug product, net of the value of any PAs or ordinary commercial terms.

Prohibition of Private Labeled Generic Drugs

Also effective May 15, 2010, private label generic drugs will not be eligible for listing on the Government formulary or for an interchangeability designation. As proposed, private label products are defined as including a drug product in respect of (a) a manufacturer applying to benefit designation or interchangeability designation, which manufacturer does not (i) directly fabricate the product, (ii) control a person that directly fabricates the product or (iii) control the person that directly fabricates the product; (b) a manufacturer which does not have an arms length relationship with an operator of a pharmacy; and (c) a product is to be supplied under a marketing arrangement associating the product with an operator of a pharmacy.

New Mark-Up Limits

Four categories will replace the current single permitted mark-up. Effective May 15, 2010, mark-ups will be increased to 10% for pharmacies in rural and under-serviced areas and 8% in urban areas, unless the pharmacy has not purchased at least 75% of listed drug products from a comprehensive wholesaler (defined as having a principal business in the distribution of pharmaceutical and other consumer products, that has carried stock and has available for sale at least 80% of the listed drug products and listed substances on the Formulary, which is prepared to supply products to operators that regularly order from wholesalers and pays the wholesalers, and has arms length relationships with manufacturers and operators of pharmacies.) If purchases are less than 75% of products purchased from a comprehensive wholesaler, the mark-up is 5%. The maximum mark-up would be $125 per listed drug product.

Increased Dispensing Fees and Other Funding

Four categories will replace the current single permitted dispensing fee. The new fees are as follows: Category 1 - $8.00, Category 2 - $9.00, Category 3 - $10.00, Category 4 - $11.00. Provision is made for annual increases starting in April 1, 2011 and continuing until April 1, 2014. Categories will be set based on criteria that include the Rural Index of Ontario, the number of pharmacies in a geographic area served by a pharmacy, the distance between pharmacies, and the volume of claims submitted by a pharmacy.

In addition to the changes proposed to legislation and regulations, the Government has also announced plans to compensate pharmacists for additional services and to increase funding for the successful MedsCheck Program.


The changes in the rules with respect to PAs are going to require significant adjustment to the business model for pharmacy services in Ontario.

Manufacturers of generic products will also face adjustments, both in terms of their relationships with customers and with the Government. The impact on agreements with the Government of Ontario and the impact on the limitations on prices in other markets (where the Government is not the payor) will need to be carefully considered, particularly in jurisdictions where a best available price rule is in place.

While the distribution of brand name products is not the focus of the changes, many of the changes have system-wide implications including, initially the changes to the definition of rebates and, over the longer term, the decision of the Government to directly impose limitations on prices in the private as well as the public market.

For the private market, including sponsors of employer-sponsored supplemental health plans, the proposed reduction in the prices of generic drugs will be welcomed.


The Bill has received second reading. The Government has invited comments on the proposed regulations until May 8, 2010. There has been no announcement of public hearings on the legislative changes. Both the regulations and the legislative changes are going to attract considerable comment and it is to be expected that the final versions of each set of proposals will reflect, to some extent, such further comment. We will provide further updates on legislative and regulatory developments as warranted.

About BLG

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions